Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Resulting from the merger of BioAlliance Pharma (France) and Topotarget (Denmark) in July 2014, Onxeo is a new leader in European biotechnology. Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. Through bringing pioneering drugs to market, the company wants to improve patients’ lives, fund continuous investment in R&D of orphan diseases, and create value for all company’s stakeholders and shareholders. It has three strategic programs in advanced development and two products already registered in the European and US markets, demonstrating its teams’ expertise and know-how.
49 boulevard du Général Martial Valin
75015 PARIS, France
Tel: +33 (0)1 45 58 76 00
Fax: +33 (0)1 45 58 08 81
Investors: investors@onxeo.com
Email: contact@onxeo.com
Website: www.onxeo.com
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
See our Cookie Privacy Policy Here
